Formuepleje A S Lowers Holdings in Boston Scientific Corporation $BSX

Key Points

• Formuepleje A S cut its Boston Scientific stake by 77.1% in the second quarter, selling 87,609 shares and retaining 26,036 shares worth approximately $1.11 million.
• Institutional ownership remains high at 89.07%, while CEO Michael Mahoney and director Edward Ludwig made notable insider purchases totaling nearly $9.4 million over the past 90 days.
• Boston Scientific exceeded quarterly earnings and revenue expectations, but its outlook faces risks from cyberattack-related shipment disruptions, product recalls and reduced analyst price targets. Analysts nonetheless maintain a “Moderate Buy” consensus with an average target of $71.62.

Formuepleje A S decreased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 77.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,036 shares of the medical equipment provider's stock after selling 87,609 shares during the quarter. Formuepleje A S's holdings in Boston Scientific were worth $1,111,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in BSX. BlackRock Inc. purchased a new position in Boston Scientific during the 2nd quarter valued at about $5,534,781,000. California State Teachers Retirement System lifted its position in shares of Boston Scientific by 4,113.5% in the 2nd quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider's stock worth $4,136,078,000 after purchasing an additional 94,609,083 shares during the period. State Street Corp boosted its stake in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider's stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Primecap Management Co. CA bought a new position in shares of Boston Scientific during the second quarter valued at approximately $2,156,233,000. Finally, Capital World Investors increased its holdings in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider's stock valued at $2,588,953,000 after buying an additional 502,627 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Michael Mahoney acquired 186,240 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward Ludwig bought 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Shipping operations are being restored after a cyberattack. Boston Scientific has begun resuming product shipments, suggesting the disruption may be contained and reducing concerns about a prolonged impact on revenue and customer relationships. Boston Scientific begins to restore shipping after cyberattack
• Positive Sentiment: Interventional cardiology and vascular therapy growth remains a key support. ICVT sales reportedly increased 15%, helped by demand for coronary therapies, new devices and strategic deals. Sustained momentum in this business could help offset pressure elsewhere. Boston Scientific's ICVT Business Gains Momentum
• Positive Sentiment: Clinical progress may expand the heart-failure opportunity. The completion of the LUX-Dx TRENDS study provides additional data on Boston Scientific’s implantable monitoring technology, although the commercial impact depends on study results and adoption. Boston Scientific’s LUX-Dx TRENDS Study
• Neutral Sentiment: Heavy call-option activity indicates some traders are positioning for a rebound, but options flows do not guarantee future stock performance. Stock Traders Buy High Volume of Call Options on Boston Scientific
• Negative Sentiment: Product recalls remain a significant overhang. Boston Scientific recalled Infinion CX spinal-cord-stimulator leads because of fracture risk following 1,081 injury reports, while additional worldwide recalls could increase costs, regulatory scrutiny and liability exposure. Boston Scientific Recalls Spinal Cord Stimulator Leads
• Negative Sentiment: The cyberattack disrupted shipments, and concerns about weaker 2026 guidance and broader business pressure have weighed on the outlook. The recent decline before the latest recovery reflects investor caution despite Boston Scientific’s prior earnings and revenue beats. Cyberattack and Weak 2026 Outlook Weigh on BSX

Boston Scientific Stock Performance

Shares of BSX stock opened at $47.85 on Monday. The business's fifty day simple moving average is $46.90 and its 200-day simple moving average is $55.60. The company has a market cap of $69.35 billion, a PE ratio of 19.37, a PEG ratio of 1.10 and a beta of 0.57. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. During the same quarter last year, the firm earned $0.75 EPS. The business's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Bank of America reduced their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a "buy" rating for the company in a research note on Monday, May 18th. Royal Bank Of Canada reduced their price target on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, July 30th. Mizuho decreased their price objective on Boston Scientific from $90.00 to $70.00 and set an "outperform" rating for the company in a research note on Wednesday, July 15th. Wolfe Research downgraded Boston Scientific from an "outperform" rating to a "peer perform" rating in a research report on Friday, May 29th. Finally, Truist Financial cut their target price on Boston Scientific from $62.00 to $57.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source